Raymond James Upgrades Trustmark to Outperform, Announces $34 Price Target
Raymond James analyst Michael Rose upgrades Trustmark (NASDAQ:TRMK) from Market Perform to Outperform and announces $34 price target.
Piper Sandler Maintains Neutral on Trustmark, Lowers Price Target to $31
Piper Sandler analyst Brad Milsaps maintains Trustmark (NASDAQ:TRMK) with a Neutral and lowers the price target from $36 to $31.
Why Grom Social Enterprises Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares surged 85% to $2.2200. Sonoma Pharmaceuticals and EMC Pharma announced Department of Defense DAPA registration for Microcyn(R) Rx products.
11 Financials Stocks Moving In Wednesday’s Intraday Session
Gainers Alvarium Tiedemann Hldgs (NASDAQ:ALTI) stock increased by 98.7% to $18.5 during Wednesday’s regular session. As of 12:30…
Trustmark Q4 EPS $0.68 Beats $0.57 Estimate
Trustmark (NASDAQ:TRMK) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.57 by 19.3 percent. This is a 61.9 percent increase over earnings of $0.42 per share from the same
Earnings Scheduled For January 24, 2023
Companies Reporting Before The Bell
• GATX (NYSE:GATX) is expected to report quarterly earnings at $1.44 per share on revenue of $327.63 million.
Trustmark Corp Reports, On Dec 31, 2022, Trustmark National Bank Agreed To Settlement In Relating To Litigation Involving Stanford Financial Group
On December 31, 2022, Trustmark National Bank (“Trustmark”) agreed to a settlement in principle (the “Settlement”) relating to litigation involving the Stanford Financial Group that includes a